And in June.
The United States "Global Standardized Medical System Consortium" was established, encompassing many pharmaceutical companies, including top-tier enterprises like Pfizer, Johnson & Johnson, Merck... and several others, including Weiler Pharmaceuticals.
Within the consortium, member countries have priority advantages in medicine, standards, and getting new drugs through FDA reviews.
At this moment!
Weiler Pharmaceutical's newly launched drug, Mistrexin, became a flagship product to replace OxyContin, quickly entering many markets.
Even!
To actively cooperate with the "New Consortium" model, Weiler Pharmaceuticals temporarily refused to provide drugs to companies outside the system.
This move attracted the attention of countless markets and also sparked various discussions and controversies.
Weiler Pharmaceuticals stated that their reasons for adopting this model included FDA requirements and the comprehensive issues of drug side effects and other factors...
